Table 1 Baseline characteristics of included patients
Total (N = 14) | |
|---|---|
Age (years)+ | 70 (62, 73) |
Female sex | 7 (50%) |
Age-adjusted CCI+ | 9.5 (9, 11) |
Primary cancer | |
Multiple myeloma | 2 (14%) |
Breast | 2 (14%) |
Lung | 1 (7%) |
RCC | 1 (7%) |
Thyroid | 2 (14%) |
Prostate | 2 (14%) |
Other | 4 (29%) |
Katagiri classification | |
Slow growth | 5 (36%) |
Moderate growth | 5 (36%) |
Rapid growth | 4 (29%) |
Additional sites of metastases | 9 (64%) |
Lung | 5 (36%) |
Lymph nodes | 4 (29%) |
Liver | 2 (14%) |
Other | 1 (7%) |
Systemic therapy | 12 (86%) |
Neoadjuvant | 9 (82%) |
Adjuvant | 11 (92%) |
Radiation therapy | 8 (57%) |
Neoadjuvant | 7 (88%) |
Adjuvant | 5 (63%) |
Follow-up (years)+ | 1.4 (1.2, 2.8) |